A dual-labeled cRGD-based PET/optical tracer for pre-operative staging and intraoperative treatment of colorectal cancer.

ABSTRACT: cRGD peptides target integrins associated with angiogenesis (e.g., α_vβ₃) and cancer, and have been used as binding ligands for both positron emission tomography (PET) and near-infrared fluorescence (NIRF) optical imaging. This study introduces the hybrid tracer cRGD-ZW800-1-Forte-[⁸⁹Zr]Zr-DFO, which is based on a novel zwitterionic fluorophore structure that reduces non-specific background uptake during molecular imaging of tumors. An in vitro binding assay was used to validate tracer performance. 10 nmol ZW800F-cRGD-Zr-DFO was injected in mice (n=7) bearing orthotopic human colorectal tumors (HT29-luc2) for tumor detection with NIRF imaging. Subsequently, ZW800F-cRGD-Zr-DFO was loaded with ⁸⁹Zr and 10 nmol cRGD-ZW800-1-Forte-[⁸⁹

SUBMITTER: Sibinga Mulder BG 

PROVIDER: S-EPMC6261878 | biostudies-literature | 2018

REPOSITORIES: biostudies-literature